| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786846 | European Journal of Surgical Oncology (EJSO) | 2018 | 6 Pages |
Abstract
The pre-treatment values of the angiogenic markers did not correlate with the clinical course of the disease. However, cEPCs levels were significantly higher in sarcoma patients with progressive disease compared to those with stable disease and should be further evaluated as early markers of disease progression in sarcoma patients. VEGF-A and angiopoetin-2 clearly play a role as mediators of the vasculogenesis contributing to tumor progression.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ioannis Karampinis, Elena Joas, Anna Dreyer, Ulrich Ronellenfitsch, Jens Jakob, Peter Hohenberger, Kai Nowak,